Date of Award
Open Access Thesis
Master of Medical Science (MMSc)
John Krystal, MD
Alcohol use disorder is one of the most prevalent mental health disorders worldwide, treatment options are limited, and relapse rates are high. There remains an urgent need for effective treatments. Research involving the therapeutic potential of classic hallucinogens has reemerged in recent decades and the hallucinogen psilocybin has shown some promise in early studies. We aim to assess the efficacy of psilocybin in treating alcohol use disorder with a 10-week double blind randomized double dummy crossover control trial comparing psilocybin-assisted psychotherapy to ketamine-assisted psychotherapy in individuals with alcohol use disorder. Our primary outcome will be the mean percent heavy drinking days in the four-week periods following drug administration sessions among participants in both treatment groups. We hope that our results will provide further evidence for the therapeutic role of psilocybin in addiction and that our study design may serve as a model for future randomized controlled trials of psychedelics.
Gruppo, Katherine, "Psilocybin-Assisted Therapy: A Double-Blind Randomized Controlled Trial" (2019). Yale School of Medicine Physician Associate Program Theses. 51.
This Article is Open Access